Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression
Conditions
Oligometastatic Disease · Oligoprogression · Toxicity Due to Radiotherapy · Quality of Life
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
BC Cancer, Kelowna, British Columbia, Canada
BC Cancer, Prince George, British Columbia, Canada
Contact: Principal Investigator (Robert A Olson)BC Cancer, Surrey, British Columbia, Canada
BC Cancer, Vancouver, British Columbia, Canada
BC Cancer - Victoria, Victoria, British Columbia, Canada
Health Sciences North Research Institute, Greater Sudbury, Ontario, Canada
Contact: Principal Investigator (Andrew Pearce)Princess Margaret Cancer Centre | University Health Network, Toronto, Ontario, Canada
Contact: Principal Investigator (Chiaojung Jillian Tsai)University Hospital Galway, Galway, Connacht, Ireland
Contact: Principal Investigator (Ronan McDermott)St. Luke's Radiation Oncology Network, Dublin, Dublin, Ireland
Contact: Principal Investigator (Lorna Keenan)Mater Private Hospital, Dublin, Leinster, Ireland
Contact: Principal Investigator (Daniel Cagney)Beacon Hospital, Dublin, Leinster, Ireland
Contact: Principal Investigator (Alina Mihai)Cork University Hospital, Cork, Munster, Ireland
Contact: Principal Investigator (Aisling Barry)Bon Secours Radiotherapy Cork in Partnership with UPMC Hillman Cancer Centre, Cork, Munster, Ireland
Contact: Principal Investigator (Paul Kelly)UPMC Whitfield Hospital - Waterford, Waterford, Munster, Ireland
Contact: Principal Investigator (Ciara Lyons)
Study leads
Robert Olson, MD, MSc, FRCPC
Principal Investigator
BC Cancer - Prince George